Lithium in Breast Milk and Nursing Infants: Clinical Implications

Adele C. Viguera, M.D., M.P.H.
D. Jeffrey Newport, M.D.
James Ritchie, Ph.D.
Zachary Stowe, M.D.
Theodore Whitfield, Sc.D.
Juliana Mogielnicki, B.A.
Ross J. Baldessarini, M.D.
Amanda Zurick, B.A.
Lee S. Cohen, M.D.

Objective: Current practice guidelines discourage use of lithium during breast-feeding, despite limited data. This study aimed to quantify lithium exposure in nursing infants.

Method: In 10 mother-infant pairs, the authors obtained assays of lithium in maternal serum, breast milk, and infant serum and indices of infant renal and thyroid function.

Results: Maternal serum, breast milk, and infant serum daily trough concentrations of lithium averaged 0.76, 0.35, and 0.16 meq/liter, respectively, each lithium level lower than the preceding level by approximately one-half. No serious adverse events were observed, and elevations of thyroid-stimulating hormone, blood urea nitrogen, and creatinine were few, minor, and transient.

Conclusions: Serum lithium levels in nursing infants were low and well tolerated. No significant adverse clinical or behavioral effects in the infants were noted. These findings encourage reassessment of recommendations against lithium during breast-feeding and underscore the importance of close clinical monitoring of nursing infants.

In clinical practice, use of lithium during lactation has been discouraged and typically considered contraindicated in breast-feeding (1–3). These cautious recommendations arise from concerns that lithium may be secreted at high levels in breast milk and infants may inefficiently clear lithium, thereby increasing their risk for significant drug exposure and toxicity (1–4). However, the evidence underlying such concerns is limited. Typically, milk/maternal plasma levels are used as a proxy for infant exposure instead of infant serum lithium levels (1–4). Accordingly, we now report concentrations of lithium in breast milk paired with both maternal and infant serum and also examine renal and thyroid indices in 10 lithium-exposed infants.

The samples were collected within 10–14 hours of each mother’s last daily dose of lithium between an average of 8 to 27 weeks postpartum. Six mother-infant pairs provided two or more samples, and four women provided segmented milk samples across a single breast-feeding to test for a gradient of lithium excretion.

Repeated measurements were pooled to provide individual subject averages and then across subjects to provide sample means and standard deviations. In addition, we calculated within-subject-pair ratios for: 1) lithium concentrations in milk/maternal serum, 2) lithium in infant serum/breast milk, and 3) lithium in infant/maternal serum. We also examined correlations (Pearson’s r) of lithium dose (mg/day) with maternal serum, breast milk, and infant serum lithium concentrations and of infant serum levels with TSH, blood urea nitrogen, and creatinine based on within-subjects means. Analyses used commercial microcomputer programs (STATA, College Station, Tex.).

Results

The 10 mother-infant pairs contributed a total of 26 samples between 8.1 weeks postpartum (SD=8.8, range=1–32) and 27.5 weeks (SD=19.6, range=7–55) (Table 1). Infants were breast-fed an average of 4.03 months (SD=2.28). The maternal lithium dose averaged 850 mg/day (SD=600–1200), with corresponding daily trough serum concentrations of 0.76 meq/liter (SD=0.29, range=0.41–1.31). Breast milk lithium concentration averaged 0.35 meq/liter (SD=0.10, range=0.19–0.48), with paired infant serum concentrations of 0.16 meq/liter (SD=0.06, range=0.09–0.25). Infant blood urea nitrogen concentration averaged 6.2 mg/dl (SD=2.1, range=3.0–9.2) and creatinine averaged 0.28 mg/dl (SD=0.6, range=0.18–0.40 mg/dl), and the mean blood urea nitrogen/creatinine ratio was 23.0 mg/dl (SD=11.5, range=10.0–51.1). Serum TSH was 2.4...
mg/dl (SD=1.88, range=1.23–7.30). No statistically significant correlations of these measures with any measure of lithium concentration were found (data not shown).

The ratio of breast milk to maternal serum lithium concentration averaged 0.53 meq/liter (SD=0.15, range=0.34–0.70), the infant serum/breast milk lithium ratio was 0.50 (SD=0.27, range=0.25–0.92), and the infant/maternal serum lithium concentration ratio was 0.24 (SD=0.14, range=0.11–0.56). Analysis of segmented breast milk in four mothers demonstrated no concentration gradient from foremilk to hindmilk for lithium.

No acute observable growth or developmental delays were reported by mothers for any infants. However, there were several instances of elevated infant serum concentrations of TSH, blood urea nitrogen, and creatinine. One male infant had a slightly elevated TSH level (7.31 µU/ml) (normal infant levels=0.5–6.3 µU/ml [5]) at 8 weeks following exposure during pregnancy from week 34 to delivery. Because thyroid function had been normal at neonatal screening, cessation of breast-feeding was recommended for this infant. No significant changes in the infant’s behavior were noted, but the mother decided to discontinue taking lithium and to nurse her infant. When retested 8 weeks later, TSH was normal (TSH=2.07 µU/ml). Two other infants had slightly elevated blood urea nitrogen levels (19–22 mg/dl versus a normal infant range of 5–15 mg/dl [5]) but with no clinical signs of hypovolemia. In a fourth infant, the creatinine level rose slightly over several months, from 0.3 to 0.6 mg/dl (normal infant range=0.2–0.4 mg/dl [5]), and returned to normal a year later (creatinine=0.2 mg/dl).

Discussion

To our knowledge, this is the largest available study of maternal-infant pairs examining serum and breast milk concentrations of lithium and concurrent infant thyroid and renal function. The study is limited in size and duration and includes a selected sample of well educated, motivated, and clinically stable women with bipolar disorder receiving lithium monotherapy. Our findings, therefore, may not generalize to more heterogeneous populations of nursing women with bipolar disorder. In addition, other monitoring procedures, such as baseline infant ECG assessments, 24-hour creatinine clearance, and formal neurobehavioral testing, were not included and may be important to consider.

Despite the study’s limitations, the findings suggest that serum lithium concentrations are substantially lower in nursing infants than previous estimates (1, 6). Lithium concentrations in infant serum (0.16 meq/liter), breast milk (0.35 meq/liter), and maternal serum (0.76 meq/liter) followed an approximate “rule of halves.” Breast milk contained about half the concentration of maternal serum,
BRIEF REPORTS

and infant serum had about half the level in breast milk, so that infant serum contained about one-quarter the concentration of lithium in maternal serum.

In contrast to many lipophilic psychotropic drugs that appear at their highest concentrations in relatively lipid-rich subsamples of hindmilk, hydrophilic lithium showed no such concentration gradient. Previous studies have failed to control for milk sampling when calculating the milk/maternal plasma ratio for psychotropics as a measure of infant exposure, which may misleadingly suggest that lithium is present in higher concentrations in foremilk, based on experience with lipophilic drugs (2).

Overall, moderate exposure to lithium through breast milk was well tolerated, with infant levels averaging 0.16 (never >0.25) meq/liter and with no obvious adverse effects on development. There were only occasional, minor, and transient laboratory abnormalities even after prolonged exposure to lithium through breast milk. We caution, however, that the risk for thyroid dysfunction and renal impairment from exposure to lithium through breast milk cannot be quantified securely. Infant hypothyroidism is a serious condition and can lead to mental and growth retardation, impaired tissue perfusion, constipation, and poor muscle tone. Moreover, even though early thyroid hormone replacement can avoid these adverse outcomes, in most cases, clinical signs of hyperthyroidism are not obvious soon after birth. Currently, some state laws mandate that all newborns be screened for hypothyroidism and other disorders. It is noteworthy that all newborns in our sample had normal neonatal thyroid assays despite prolonged exposure to lithium in utero and the complete passage of maternal lithium across the placenta (6).

The elevated serum blood urea nitrogen level noted in two of 10 infants highlights the importance of infant fluid status. Because renal function and lithium clearance are sensitive to perturbations in fluid volume, we recommend added vigilance during exposure to lithium through nursing, especially with fever, gastrointestinal illness, or other loss of fluid and electrolytes. Severe fluid loss could lead to toxic retention of lithium as sodium is lost, and lithium clearance can be compromised further by co-administration of nonsteroidal analgesic-antipyretic agents such as ibuprofen. Clinical signs of lithium toxicity, including lethargy, poor feeding, and hypotonia, are generally reversible with early aggressive treatment with intravenous hydration (1, 2).

Currently, formal guidelines for therapeutic drug monitoring of mood stabilizers are not available (1, 2). However, because monitoring of indices of thyroid and renal function is standard for adults treated with lithium, similar recommendations are appropriate for nursing infants exposed to lithium. Laboratory monitoring should include assays of infant serum lithium and TSH, blood urea nitrogen, and creatinine levels, preferably in the immediate postpartum period up to 6 weeks of age. Based on clinical experience, we recommend using an experienced phlebotomist and favor obtaining laboratory values between 4 and 6 weeks of age, when venous access is easier and potentially less stressful for the infant. Of note, we found no negative consequences of obtaining laboratory values after the immediate postpartum period. As long as an infant is breast-fed by a woman taking lithium, laboratory monitoring should continue—on average every 8–12 weeks or as clinically indicated.

Despite the absence of treatment-emergent adverse events in our small cohort, we caution that breast-feeding while taking lithium should be considered appropriate only for carefully selected women with bipolar disorder. Suitable clinical characteristics include the following: 1) stable maternal mood, 2) lithium monotherapy or at least a simple medication regimen, 3) and adherence to infant monitoring recommendations, as well as a 4) a healthy infant and 5) a collaborative pediatrician. Further studies assessing larger cohorts of nursing infants are needed to quantify lithium exposure during lactation and to examine the spectrum of possible adverse effects as well as to define optimal monitoring requirements.

Presented as a poster at the 158th annual meeting of the American Psychiatric Association, Atlanta, May 21–26, 2005. Received Oct. 19, 2005; revision received March 24, 2006; accepted June 26, 2006.

Supported in part by NIMH grant MH-01609 and a National Alliance for Research on Schizophrenia and Depression Young Investigators Award (to Dr. Viguera) and P50-MH-8036 (to Dr. Stowe) for breast milk analysis, a Stanley Research Institute grant (to Dr. Cohen), a grant from the Bruce J. Anderson Foundation, and by the McLean Private Donors Psychopharmacology Research Fund (to Dr. Baldessarini).

Dr. Viguera has received grants/research support from AstraZeneca, Berlex Laboratories, Eli Lilly and Company, Forest Pharmaceuticals, GlaxoSmithKline Pharmaceuticals, Harvard Medical School’s Scholars in Medicine Fellowship Award, Janssen Pharmaceuticals, NARSAD: The Mental Health Research Association, NIMH, Pfizer Pharmaceuticals, Sepracor, Stanley Medical Research Institute, and Wyeth-Ayerst Pharmaceuticals. She has served on the advisory boards for GlaxoSmithKline Pharmaceuticals and Novartis Pharmaceuticals and has been on the speaker’s bureau for Eli Lilly and Company, GlaxoSmithKline Pharmaceuticals, Novartis Pharmaceuticals, and Wyeth-Ayerst Pharmaceuticals. Neither she nor her family members hold equity positions in biomedically/pharmaceutical corporations.

Dr. Cohen has received grants/research support from AstraZeneca Pharmaceuticals, Berlex Laboratories, Eli Lilly and Company, Forest Pharmaceuticals, GlaxoSmithKline Pharmaceuticals, Janssen Pharmaceuticals, NIMH, Sepracor, the Stanley Medical Research Institute, and Wyeth-Ayerst Pharmaceuticals. He has served on advisory boards for Eli Lilly and Company, GlaxoSmithKline Pharmaceuticals, Janssen Pharmaceuticals, Novartis Pharmaceuticals, Ortho-McNeil Pharmaceuticals, and Wyeth-Ayerst Pharmaceuticals and has been on the speaker’s bureaus of AstraZeneca Pharmaceuticals, Berlex Pharmaceuticals, Eli Lilly and Company, Forest Pharmaceuticals, GlaxoSmithKline Pharmaceuticals, Janssen Pharmaceuticals, Pfizer Pharmaceuticals, and Wyeth-Ayerst Pharmaceuticals. Neither he nor...
his family members hold equity positions in biomedical or pharmaceutical corporations.

Dr. Newport has received research support from Eli Lilly and Company, GlaxoSmithKline Pharmaceuticals, Janssen Pharmaceuticals, NARSAD: The Mental Health Research Association, NIH, and Wyeth-Ayerst Pharmaceuticals. He has served on the speaker’s bureaus and/or received honoraria from AstraZeneca Pharmaceuticals, Eli Lilly and Company, GlaxoSmithKline Pharmaceuticals, Pfizer Pharmaceuticals, and Wyeth-Ayerst Pharmaceuticals. He has not served on advisory boards. Neither he nor his family members hold equity positions in biomedical or pharmaceutical corporations.

Dr. Stowe has received research support from GlaxoSmithKline Pharmaceuticals, NIH, Pfizer Pharmaceuticals, and Wyeth-Ayerst Pharmaceuticals. He has served on the advisory boards for Bristol-Myers Squibb, GlaxoSmithKline Pharmaceuticals, Pfizer Pharmaceuticals, and Wyeth-Ayerst Pharmaceuticals. He has served on speaker’s bureaus and/or received honoraria from Eli Lilly and Company, Forrest Pharmaceuticals, GlaxoSmithKline Pharmaceuticals, Pfizer Pharmaceuticals, and Wyeth-Ayerst Pharmaceuticals. Neither he nor his family members hold equity positions in biomedical or pharmaceutical corporations.

Dr. Baldessarini is a consultant or research collaborator with Au-ritec Pharmaceuticals, Biotrofix, Inc., Branfman Foundation, Bruce J. Anderson Foundation, IFI Patent Intelligence, Janssen Pharmaceuticals, JDS Pharmaceuticals, Eli Lilly and Company, Merck & Co., Inc., NIH, NeuroHealing Pharmaceuticals, Novartis Pharmaceuticals, SK Biopharmaceuticals, and Solvay Corporations. He is not a member of speaker’s bureaus, nor does he or any family member hold equity positions in biomedical or pharmaceutical corporations. All other authors report no competing interests.

References